TO THE EDITOR
The prognosis of patients with relapse of acute myeloid leukemia (AML) after allogeneic stem cell transplantation (SCT) is poor. Remissions induced by intensive chemotherapy were short in most cases, and the median survival of the responders was 8 months. Second transplants are limited due to severe toxicity and high treatment-related mortality (TRM). In most large series, the 3-year leukemia-free survival after a second transplant is about 10%. 1 The transfusion of lymphocytes from the original stem cell donor (DLT) has been successful only in a minority of patients with AML. 2 Unlike in chronic myelogenous leukemia (CML), the rapid pace of the disease seems to be a major obstacle to adoptive immunotherapy in acute leukemia. Therefore, intensive chemotherapy has been used prior to, or with DLT. It has improved response rates, but not survival, mostly because of a high TRM. Insufficient antigen presentation by the leukemic blasts is regarded as another reason for the inferior results in AML. In CML, the good response might be due to the fact that dendritic cells (DC) as the most potent antigen-presenting cells (APC) are part of the leukemic clone. In contrast, AML blasts are generally poor APC, showing reduced or missing expression of costimulatory molecules, and fail to induce significant T-cell proliferation. However, AML blasts can be differentiated towards cells with a DC-like morphology and immune phenotype in vitro in about 70% of cases, when cultured in the presence of certain cytokine combinations. In functional assays, the capacity of the leukemia-derived DC to elicit a specific cytotoxic T-cell response was markedly increased as compared to the naïve blasts. 3 Therefore, we initiated a prospective phase I/II trial using a modified protocol of adoptive immunotherapy to treat AML relapse post-transplant. In patients receiving immunosuppressive medication at the time of relapse, immediate cessation was the first step of treatment. If the patient was not on immunosuppression, or if stop of immunosuppression was not effective after a maximum of 2 weeks, chemotherapy was given for control of leukemic proliferation. To reduce toxicity, lowdose cytosine arabinoside (LdAraC; 2 Â 10 mg/m 2 /day s.c. given on an outpatient basis for 14 days) was used as first-line chemotherapy. The course was repeated once after 2 weeks' time. Reinduction of complete remission was not intended. Only in case of progressive leukemia with LdAraC, intensive chemotherapy, including anthracyclines, was administered. Regardless of remission status and regeneration of hematopoiesis, the patients then received a single transfusion of G-CSF-mobilized donor blood cells (MDBCT) without immunosuppressive prophylaxis. From day þ 1 to þ 28, recombinant hGM-CSF (molgrammostim, Leukomaxt) was given s.c. or as continuous i.v. infusion to improve antigen presentation in vivo. The first three patients received 300 mg/day. Owing to pulmonary toxicity in two cases, the dosage was reduced to 75 mg/m 2 /day. GM-CSF had to be discontinued in case of increasing numbers of blasts in the peripheral blood (PB) and in case of acute graft-versus-host disease (aGvHD) of 4grade II. Inclusion criteria for the study were hematological relapse after allogeneic SCT, an HLA-matched or one minor AG-mismatched family or unrelated donor, and demonstration of persistent mixed chimerism at the time of relapse. Patients with extramedullary relapse were excluded, as were patients with more than 80% of blasts in PB or bone marrow (BM), who received intensive chemotherapy up front. AGvHD 4 grade I or extensive chronic graft-versus-host disease (cGVHD) at the time of relapse were further exclusion criteria. Control of leukemic proliferation by LdAraC, that is reduction of blasts in the PB by at least 50%, and remission rate on day þ 30 after MDBCT were the primary end points of the study. Secondary end points included overall survival (OAS), event-free survival (EFS), TRM as defined by death in remission of any cause, and incidence of GvHD. The study was approved by the ethical committee at the university of Munich, Germany. Informed consent was obtained from all patients and family donors. The protocol is summarized in Figure 1 .
Starting in January 1995, all 22 consecutive patients at the university of Munich, Germany, who fulfilled the inclusion criteria, were enrolled. Additionally, two patients were included at the centers of Regensburg, Germany, and Huddinge, Sweden, shortly before the study was closed in March 2001. Patients' characteristics are summarized in Table 1 .
None out of seven patients on immunosuppressive treatment at the time of relapse responded to immediate stop of immunosuppression. However, mild chemotherapy using LdAraC alone led to disease control in 11 cases. In nine of these patients, neutrophil counts did not drop below 500/ml. In contrast, 13 patients required intensive chemotherapy and uniformly developed pancytopenia. At the time of donor cell transfusion, five patients had persisting leukemic blasts in the PB. All patients proceeded to MDBCT within a median of 6 days from the end of chemotherapy. GM-CSF was started at day þ 1. It had to be discontinued because of aGvHD 4 grade II in eight cases and increasing numbers of blasts in three. In seven patients with residual leukemia at day þ 30, application of GM-CSF was prolonged.
Three patients were not evaluable for disease response because of early death. Of the remaining patients, 14 (67,7%) responded with complete clearance of leukemia from PB and BM. In univariate analysis, three factors were associated with a better response: monocytic differentiation of leukemic blasts (CR in 9/9 patients, P ¼ 0.008), initial disease control by LdAraC (CR in 10/11 patients P ¼ 0.02), and aGvHD Xgrade II after MDBC transfusion (CR in 10/11 patients, P ¼ 0.02). After MDBCT, donor cell chimerism in PB and BM increased rapidly in responding patients, reaching a median of 100% at day þ 30 (range for 498% donor cells in BM: day þ 21-þ 60). During follow up, decreasing donor chimerism preceded hematological relapse in three cases, whereas full chimerism persisted over years in patients in remission.
Seven patients with refractory disease died from leukemia, as did seven patients who developed secondary relapse at a median of 9 (range 1-46) months from treatment. TRM was 25%. It was limited to the first 100 days and occurred exclusively in patients with an unrelated donor. AGvHD was seen in 19 patients at a median of 22 days from MDBCT. It could be treated by conventional immunosuppression in all but one case. CGvHD was mainly limited to the skin and occurred in 10 out of 16 patients who survived more than 3 months. Among the surviving patients, the median follow up is 37 (range 24-71) months. The 2-year OAS and DFS for the entire cohort was 29 and 21% ( Figure 2 ). The median survival was 10 months for responding and 2.9 months for nonresponding patients, and the probability of survival at 2 years from treatment was 0.45 and 0.0, respectively. To date, four patients are in CCR between 24 and 73 months from MDBCT. A longer remission post-transplant (P ¼ 0.003), disease control by LdAraC (P ¼ 0.01), and cGvHD after MDBCT (P ¼ 0.008) were associated with better survival (log rank).
In this study, three new elements were introduced, as compared to the traditional strategy of adoptive immunotherapy using DLT with or without intensive chemotherapy: the use of LdAraC as first-line chemotherapy, the transfusion of MDBC instead of unstimulated lymphocytes, and the use of GM-CSF after donor cell transfusion for further stimulation of alloimmunity. LdAraC was used prior to MDBCT to avoid hospitalization and to minimize chemotherapy-related toxicity. In 45% of patients, leukemic proliferation could be controlled by LdAraC alone, allowing nine patients to be completely treated as outpatients before MDBCT. Disease control by LdAraC was predictive for achieving a CR at day þ 30, and for survival ( Figure 3) . TRM was 18% after LdAraC vs 30% in the group receiving intensive chemotherapy. These data suggest that LdAraC can be used as first-line cytoreductive therapy in relapsed AML post allo-SCT prior to adoptive immunotherapy. So far no patient has lost the chance to proceed to donor cell transfusion, if initial LdAraC was not effective. On the other hand, response to LdAraC may be a surrogate marker for a less aggressive disease. Besides cytoreduction, LdAraC may also have additional effects with regard to immunotherapy, since it induces apoptosis of leukemic cells thereby promoting phagocytosis and processing of leukemia antigens by dendritic cells. 4 There are also data indicating that LD-AraC can induce differentiation of leukemic cells. 5 The transfusion of G-CSF-mobilized donor cells has been used to shorten the neutropenic phase following chemotherapy or DLT. However, MDBC may have additional effects, supporting GvL reactions. Application of G-CSF before donor cell collection results in a switch of donor T cells towards TH2 cells. Although murine studies suggest that this might lead to a GVL reaction without GVHD, 6 the clinical significance is uncertain. Additionally, a potential role of accessory cells as monocytes and NK cells has been discussed, 7 and crosspriming of leukemic or minor histocompatibility antigenes by donor-derived APC has been suggested by preclinical studies. 4 Unfortunately, we were not able to isolate crosspriming APC from our patients. Difficulties in the isolation of such cells have been reported by other groups, most likely due to the rapid disappearance of these cells into the tissue or to an increased sensitivity to isolation procedures.
Recombinant hGM-CSF has been used as postinduction support in AML. So far, it has not been used an adjuvant for adoptive immunotherapy in vivo. It was chosen in this study since it had been a constituent of all cytokine cocktails being effective for generation of AML-derived DC in vitro. 3 Although not suggested by clinical trials, the potential stimulatory effect on the malignant clone has been a concern in our study. However, increasing blast counts were only seen in three patients with chemotherapy-refractory disease. The use of GM-CSF was complicated by a pulmonary leakage syndrome in two cases at the initial dose of 300 mg/day. The problem could be circumvented by reduction of the GM-CSF dose to 75 mg/m 2 / day. The role of GM-CSF in adoptive immunotherapy could not yet been defined. Owing to the small number in the PB, it was not possible to isolate DC from responding patients in a number high enough to prove their leukemic origin. However, when leukemic blasts of nonresponding patients were cultured in the presence of GM-CSF and other cytokines, no upregulation of costimulatory molecules could be demonstrated (data not shown). Clinically, a beneficial effect of GM-CSF is supported by the better response of monocytic leukemia. Nevertheless, the role of GM-CSF for adoptive immunotherapy warrants further evaluation.
Regarding clinical efficacy, our results can be compared to DLT given with or without chemotherapy, and to second SCT. Using DLT alone, response rates from 0 to 42% have been reported. 2 The additional use of intensive chemotherapy led to CR rates in the range of 47-54%, as compared to 67% in our entire cohort and to 91% among responders to LdAraC. In terms of outcome, overall survival was comparable between the reported cohorts including ours, showing a range of 19-36% after 1 and 19-25% after 2 years. Levine et al 8 reported on 41% of patients with AML or advanced CML being alive at 2 years after response to intensive chemotherapy and MDBCT. In our study, 2-year OAS was 45% in responders and 60% in those patients whose disease was controlled by LdAraC (Figure 3) . Besides the response to LdAraC, the duration of post-transplant remission and the occurrence of cGvHD were predictive for survival. The importance of a longer remission has also been reported by others (summarized in Kolb et al 2 ) , and may be helpful to identify patients who will or will not benefit from adoptive immunotherapy. CGvHD might be associated with an ongoing GvL effect. 
Figure 3
Survival as of response to LdAraC. The solid line represents patients whose disease was controlled by LdAraC alone before MBDCT (n ¼ 11), the dashed line represents patients who required intensive chemotherapy (n ¼ 13). P ¼ 0.01.
Our approach differs from a second SCT by avoiding conditioning treatment and prophylactic immunosuppression. Comparison of the results is difficult, since in most studies on second SCT, rather heterogeneous cohorts were treated. In general, TRM rates of 41-56% have been reported for second transplants following myeloablative conditioning. 1 Keeping this in mind, approaches based on immunotherapy might be preferable in terms of toxicity. Further, TRM in our study was limited to patients with an unrelated donor. Better HLA typing may improve the results of adoptive immunotherapy in the unrelated setting. So far, little is known about the role of a second SCT with nonmyeloablative conditioning, although encouraging results have been reported. 9 However, the study population was rather small, including only seven patients with AML.
In conclusion, we feel that the use of LdAraC, MDBC, and GM-CSF is a feasible approach to the treatment of relapsed AML post allogeneic SCT. Intensive chemotherapy might not be necessary in all patients prior to adoptive immunotherapy. Patients with a longer remission post-transplant, and those who respond to LdAraC might be optimal candidates for this kind of therapy, whereas patients with early relapse may require alternative strategies. The use of GM-CSF in this setting is safe, but its clinical role remains to be defined. Relapse was the most important cause of death beyond day þ 100, whereas cGVHD was associated with better survival. Therefore, approaches involving further transfusions of donor cells or the use of stimulatory cytokines may improve the results, based on an ongoing GvL effect. However, a better understanding of the mechanisms responsible for GvL reactions and immune escape of malignant cells remain essentials for further improvement in the treatment of AML relapse post-transplant. Acute leukemia is a rare event in the natural history of Waldenstrom's macroglobulinemia, and acute lymphocytic leukemia is even less common. [1] [2] [3] [4] [5] [6] [7] [8] We present a patient who developed acute lymphocytic leukemia 22 years after being diagnosed with Waldenstrom's macroglobulinemia.
This patient was an 80-year-old man, who was diagnosed with Waldenstrom's macroglobulinemia in 1979. He had been treated continuously with chlorambucil and prednisone for more than 20 years. The doses of chlorambucil varied from 2 to 6 mg/day. In May 2001, he complained of dyspnea and easy fatigability. His physical examination was unremarkable. The CBC showed white blood cell count (WBC) 6.6 K/ml, hemoglobin (HGB) 13.4 g/dl, hematocrit (HCT) 38.8% and platelet count (PLT) 159 000/ml. The serum IgM lambda monoclonal protein was 1.93 g/dl, with decreased IgG and IgA levels. The bone marrow aspirate and biopsy was consistent with Waldenstrom's
